Klaus Lindpaintner

home / authors / klaus-lindpaintner

Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.

Articles

A New Era of Biomarker Discovery: Harnessing the Clinical Power of AI-Driven Glycoproteomics

A New Era of Biomarker Discovery: Harnessing the Clinical Power of AI-Driven Glycoproteomics

Klaus Lindpaintner

October 1st 2022

Assessment of peripheral blood protein glycosylation has recently become scalable, providing a new domain for biomarker research.

Latest Updated Articles

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 11th 2024 | Updated: September 18th 2024

CPHI Pharma Award Finalists Announced for 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Published: March 27th 2024 | Updated: June 28th 2024

AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product

Published: October 28th 2024 | Updated: November 22nd 2024

Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development

Published: November 15th 2024 | Updated: November 22nd 2024

Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs

Published: October 28th 2024 | Updated: November 22nd 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Optimizing cGMP Facility Design Space with a Hybrid Approach

Published: October 22nd 2024 | Updated: November 22nd 2024

Optimizing cGMP Facility Design Space with a Hybrid Approach

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.